Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AN9025

Small molecule · Inhibitor of RAS (wild type and mutant NRAS, KRAS isoforms, GTP-bound form) (KRAS) · developed by Adlai Nortye Biopharma Co.

Phase 1 Most advanced trial
ANL Developer
1 Registered trials

What is AN9025?

AN9025 is an orally bioavailable pan-RAS inhibitor that binds cyclophilin A, and the resulting complex binds active GTP-bound RAS to form a tri-complex. It acts on both wild-type and mutant NRAS and KRAS to inhibit RAS-dependent signaling. It is being studied in solid tumors and RAS-mutated cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
RAS (wild type and mutant NRAS, KRAS isoforms, GTP-bound form) (KRAS), Cyclophilin A (PPIA) (binding partner it blocks)
Mechanism
Inhibitor of RAS (wild type and mutant NRAS, KRAS isoforms, GTP-bound form) (KRAS)
Pathways
RAS-dependent signaling, tumor cell proliferation
Therapy area
Oncology
Developer
Adlai Nortye Biopharma Co., Ltd. (ANL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07252479 Phase 1 Solid Tumors (Phase 1) Recruiting ANL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

RAS MutationSolid Tumors (Phase 1)

Other drugs acting on KRAS

Sotorasib FDA approved ARV-806 Phase 1/2 Calderasib Phase 3 Elironrasib Phase 1/2 ERAS-0015 Phase 1 Olomorasib Phase 3 Zoldonrasib Phase 1/2

More from Adlai Nortye Biopharma Co.

AN4005 Phase 1 AN4035 Phase 1 AN8025 Phase 1 Palupiprant Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ANL page.

Follow ANL, the company behind AN9025

See ANL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.